Literature DB >> 31414210

Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.

Luis Aragão Gomes1,2, Silvia Andrea Hipp3,4, Ajeet Rijal Upadhaya3, Karthikeyan Balakrishnan3,5, Simona Ospitalieri1,2, Marta J Koper1,2,6,7, Pablo Largo-Barrientos7,8, Valerie Uytterhoeven7,8, Julia Reichwald9, Sabine Rabe9, Rik Vandenberghe2,10,11, Christine A F von Arnim12,13, Thomas Tousseyn14, Regina Feederle15,16,17, Camilla Giudici16, Michael Willem18, Matthias Staufenbiel9, Dietmar Rudolf Thal19,20,21,22.   

Abstract

Extracellular deposition of amyloid β-protein (Aβ) in amyloid plaques and intracellular accumulation of abnormally phosphorylated τ-protein (p-τ) in neurofibrillary tangles (NFTs) represent pathological hallmark lesions of Alzheimer's disease (AD). Both lesions develop in parallel in the human brain throughout the preclinical and clinical course of AD. Nevertheless, it is not yet clear whether there is a direct link between Aβ and τ pathology or whether other proteins are involved in this process. To address this question, we crossed amyloid precursor protein (APP) transgenic mice overexpressing human APP with the Swedish mutation (670/671 KM → NL) (APP23), human wild-type APP (APP51/16), or a proenkephalin signal peptide linked to human Aβ42 (APP48) with τ-transgenic mice overexpressing human mutant 4-repeat τ-protein with the P301S mutation (TAU58). In 6-month-old APP23xTAU58 and APP51/16xTAU58 mice, soluble Aβ was associated with the aggravation of p-τ pathology propagation into the CA1/subiculum region, whereas 6-month-old TAU58 and APP48xTAU58 mice neither exhibited significant amounts of p-τ pathology in the CA1/subiculum region nor displayed significant levels of soluble Aβ in the forebrain. In APP23xTAU58 and APP51/16xTAU58 mice showing an acceleration of p-τ propagation, Aβ and p-τ were co-immunoprecipitated with cellular prion protein (PrPC). A similar interaction between PrPC, p-τ and Aβ was observed in human AD brains. This association was particularly noticed in 60% of the symptomatic AD cases in our sample, suggesting that PrPC may play a role in the progression of AD pathology. An in vitro pull-down assay confirmed that PrPC is capable of interacting with Aβ and p-τ. Using a proximity ligation assay, we could demonstrate proximity (less than ~ 30-40 nm distance) between PrPC and Aβ and between PrPC and p-τ in APP23xTAU58 mouse brain as well as in human AD brain. Proximity between PrPC and p-τ was also seen in APP51/16xTAU58, APP48xTAU58, and TAU58 mice. Based on these findings, it is tempting to speculate that PrPC is a critical player in the interplay between Aβ and p-τ propagation at least in a large group of AD cases. Preexisting p-τ pathology interacting with PrPC, thereby, appears to be a prerequisite for Aβ to function as a p-τ pathology accelerator via PrPC.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-β; Cross seeding; Neuropathology; Prion protein; Tau-protein; Transgenic mice

Mesh:

Substances:

Year:  2019        PMID: 31414210     DOI: 10.1007/s00401-019-02053-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  37 in total

1.  The membrane axis of Alzheimer's nanomedicine.

Authors:  Yuhuan Li; Huayuan Tang; Nicholas Andrikopoulos; Ibrahim Javed; Luca Cecchetto; Aparna Nandakumar; Aleksandr Kakinen; Thomas P Davis; Feng Ding; Pu Chun Ke
Journal:  Adv Nanobiomed Res       Date:  2020-11-26

2.  Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation.

Authors:  Luis Aragão Gomes; Valerie Uytterhoeven; Diego Lopez-Sanmartin; Sandra O Tomé; Thomas Tousseyn; Rik Vandenberghe; Mathieu Vandenbulcke; Christine A F von Arnim; Patrik Verstreken; Dietmar Rudolf Thal
Journal:  Acta Neuropathol       Date:  2021-01-11       Impact factor: 17.088

Review 3.  Anchorless risk or released benefit? An updated view on the ADAM10-mediated shedding of the prion protein.

Authors:  Behnam Mohammadi; Feizhi Song; Andreu Matamoros-Angles; Mohsin Shafiq; Markus Damme; Berta Puig; Markus Glatzel; Hermann Clemens Altmeppen
Journal:  Cell Tissue Res       Date:  2022-01-27       Impact factor: 5.249

Review 4.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

Review 5.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

Review 6.  Synergy between amyloid-β and tau in Alzheimer's disease.

Authors:  Marc Aurel Busche; Bradley T Hyman
Journal:  Nat Neurosci       Date:  2020-08-10       Impact factor: 24.884

7.  Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum.

Authors:  Leonardo Iaccarino; Renaud La Joie; Lauren Edwards; Amelia Strom; Daniel R Schonhaut; Rik Ossenkoppele; Julie Pham; Taylor Mellinger; Mustafa Janabi; Suzanne L Baker; David Soleimani-Meigooni; Howard J Rosen; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Cereb Cortex       Date:  2021-01-01       Impact factor: 5.357

8.  The Interplay of Tau Protein and β-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally Pathogenic.

Authors:  Mahsa Pourhamzeh; Mohammad Taghi Joghataei; Soraya Mehrabi; Reza Ahadi; Seyed Mohammad Massood Hojjati; Nasrin Fazli; Seyed Massood Nabavi; Hossein Pakdaman; Koorosh Shahpasand
Journal:  Cell Mol Neurobiol       Date:  2020-07-22       Impact factor: 5.046

9.  CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia.

Authors:  Chritica Lodder; Isabelle Scheyltjens; Ilie Cosmin Stancu; Kiavash Movahedi; Ilse Dewachter; Pablo Botella Lucena; Manuel Gutiérrez de Ravé; Sarah Vanherle; Tim Vanmierlo; Niels Cremers; Hannah Vanrusselt; Bert Brône; Bernard Hanseeuw; Jean-Noël Octave; Astrid Bottelbergs
Journal:  Acta Neuropathol Commun       Date:  2021-06-08       Impact factor: 7.801

10.  Characterization of a Mouse Model of Alzheimer's Disease Expressing Aβ4-42 and Human Mutant Tau.

Authors:  Silvia Zampar; Oliver Wirths
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.